TACT

(redirected from Trial to Assess Chelation Therapy)
AcronymDefinition
TACTTactical
TACTTransistor and Component Tester
TACTTrial to Assess Chelation Therapy (NCCAM and NHLBI study)
TACTText Analysis Computing Tools
TACTThe Air Cargo Tariff (shipping)
TACTThe A Consulting Team, Inc. (consulting, software development, and training; New York City)
TACTTransonic Aircraft Technology
TACTTuned Aperture Computed Tomography
TACTTaxotere as Adjuvant Chemotherapy Trial
TACTTokyo Air Cargo City Terminal (Japan)
TACTTexas Alternative Center for Teachers (Mission, TX)
TACTTailored Annual Cutter Training (US Coast Guard)
TACTTotal Average Cycle Time
TACTTel Aviv City Team
TACTTotal Audit Concept Technique (DCAA)
TACTTechnology Advising and Consulting Team
TACTTransmission Automatique des Conditions de Trafic
TACTTactical Aviation Control Team
TACTTechnical Area Coordinating Team
TACTThumb Area Community Theatre (Sebewaing, Michigan)
References in periodicals archive ?
After decades of conflict between conventional physicians and alternative doctors who recognized EDTA chelation therapy as an effective treatment for coronary artery disease, the Trial to Assess Chelation Therapy (TACT) was completed in 2012.
Why the NIH Trial to Assess Chelation Therapy (TACT) should be abandoned.
The study, known as the Trial to Assess Chelation Therapy (TACT), involved 1,708 patients at 134 centers across the U.
editor of the Medscape Journal of Medicine and former editor of JAMA, facilitated the publishing of an "original article" entitled, "Why the NIH Trial to Assess Chelation Therapy (TACT) Should Be Abandoned," authored by Kimball C.
To determine whether chelation therapy is effective and safe for heart disease, the National Center for Complementary and Alternative Medicine (NCCAM) and the National Heart, Lung, and Blood Institute at the NIH launched the first large-scale, multicenter, placebo-controlled study--the Trial to Assess Chelation Therapy (TACT).
The Trial to Assess Chelation Therapy (TACT) will follow more than 2,300 patients at 100 research sites across the country for 5 years.
Perhaps the most promising advance for the treatment of diabetes since insulin came from the Trial to Assess Chelation Therapy (TACT).
The study, known as the Trial to Assess Chelation Therapy (TACT), had a double-blind, placebo-controlled, 2 x 2 factorial design, in which patients received 40 intravenous infusions of EDTA, a daily high-potency 28-component multivitamin-multim ineral formula, both treatments, or placebo.
The KU Integrative Medicine Center was an active participant in the Trial to Assess Chelation Therapy.
In 2008 Atwood (anesthesiologist at Tufts University and editor of Scientific Review of Alternative Medicine), Elizabeth Woeckner (litigator for medical boards), Robert Baratz, MD, DDS, PhD (expert witness for medical board disciplinary litigation), and Wallace Sampson, MD (professor of medicine and editor-in-chief of Scientific Review of Alternative Medicine), authored a 89-page editorial epic titled "Why the NIH Trial to Assess Chelation Therapy (TACT) Should Be Abandoned" (Medscape J Med.
The Trial to Assess Chelation Therapy (TACT) is the only large, randomized clinical trial to provide statistically significant evidence that EDTA chelation therapy with high-dose multivitamins can reduce future cardiac events in patients with known cardiovascular disease.
From March 13 to 15, 2013, the International College of Integrative Medicine (ICIM) held a summit meeting about what should be accomplished next, now that EDTA chelation therapy has been supported as a useful treatment for vascular disease by the Trial to Assess Chelation Therapy (TACT).